Short Interest in Capstone Therapeutics Corp. (NASDAQ:CAPS) Decreases By 39.0%

Posted by Stanley Muller on Sep 2nd, 2026

Capstone Therapeutics Corp. (NASDAQ:CAPS – Get Free Report) was the recipient of a large decrease in short interest during the month of August. As of August 14th, there was short interest totaling 190,290 shares, a decrease of 39.0% from the July 30th total of 311,827 shares. Currently, 1.5% of the shares of the stock are sold short. Based on an average trading volume of 1,508,069 shares, the short-interest ratio is currently 0.1 days.

Institutional Trading of Capstone Therapeutics

A hedge fund recently bought a new position in Capstone Therapeutics stock. DRW Securities LLC purchased a new stake in Capstone Therapeutics Corp. (NASDAQ:CAPS – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned 1.51% of Capstone Therapeutics as of its most recent filing with the Securities & Exchange Commission. 2.55% of the stock is owned by hedge funds and other institutional investors.

Capstone Therapeutics Price Performance

CAPS opened at $0.18 on Wednesday. Capstone Therapeutics has a 1 year low of $0.17 and a 1 year high of $1.57. The company’s 50 day simple moving average is $0.24 and its 200 day simple moving average is $0.40. The stock has a market capitalization of $3.81 million, a PE ratio of -0.06 and a beta of -1.52. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.39 and a current ratio of 0.99.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Capstone Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research report on Thursday, August 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Get Our Latest Analysis on CAPS

About Capstone Therapeutics

(Get Free Report)

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.